Načítá se...
Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
Despite effective factor replacement and various treatment schedules, there remain several challenges and unmet needs in the prophylactic treatment of hemophilia limiting its adoption and thereby posing an increased risk of spontaneous bleeding. In this regard, extended half-life (EHL) recombinant f...
Uloženo v:
| Vydáno v: | Turk J Haematol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Galenos Publishing
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6682782/ https://ncbi.nlm.nih.gov/pubmed/31088040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4274/tjh.galenos.2019.2018.0393 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|